Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

Summary

The purpose of this study is to evaluate the efficacy and safety of olmutinib 600 mg QD in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Timeline

Start

2018-03-29

Primary completion

2018-12-11

Completion

2018-12-11

Outcome

Outcome not reported

Stopped: “Study termination by the Sponsor”

Drugs

Indications